ArriVent BioPharma, Inc. (AVBP)
(Delayed Data from NSDQ)
$19.95 USD
+0.37 (1.89%)
Updated May 21, 2024 04:00 PM ET
4-Sell of 5 4
D Value F Growth F Momentum F VGM
Income Statements
Fiscal Year end for ArriVent BioPharma, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | NA | NA |
Cost Of Goods | 0 | 0 | 0 | NA | NA |
Gross Profit | 0 | 0 | 0 | NA | NA |
Selling & Adminstrative & Depr. & Amort Expenses | 75 | 37 | 52 | 0 | 0 |
Income After Depreciation & Amortization | -75 | -37 | -52 | 0 | 0 |
Non-Operating Income | 5 | 0 | 0 | NA | NA |
Interest Expense | 0 | 0 | 0 | NA | NA |
Pretax Income | -69 | -37 | -52 | NA | NA |
Income Taxes | 0 | 0 | 0 | NA | NA |
Minority Interest | 0 | 0 | 0 | NA | NA |
Investment Gains/Losses | 0 | 0 | 0 | NA | NA |
Other Income/Charges | 0 | 0 | 0 | NA | NA |
Income From Cont. Operations | -69 | -37 | -52 | NA | NA |
Extras & Discontinued Operations | 0 | 0 | 0 | NA | NA |
Net Income (GAAP) | -69 | -37 | -52 | NA | NA |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -75 | -37 | -52 | 0 | 0 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | NA | NA |
Income After Depreciation & Amortization | -75 | -37 | -52 | 0 | 0 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.14 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -32.38 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -32.38 | -28.90 | NA | NA | NA |
Fiscal Year end for ArriVent BioPharma, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | 0.00 | NA | NA | NA | 0.00 |
Cost Of Goods | 0.00 | NA | NA | NA | 0.00 |
Gross Profit | 0.00 | NA | NA | NA | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 20.68 | 0.00 | 0.00 | 0.00 | 12.18 |
Income After SG&A, R&D, and Dept/Amort Expenses | -20.68 | 0.00 | 0.00 | 0.00 | -12.18 |
Non-Operating Income | 3.26 | NA | NA | NA | 0.00 |
Interest Expense | 0.00 | NA | NA | NA | 0.00 |
Pretax Income | -17.42 | NA | NA | NA | -12.17 |
Income Taxes | 0.00 | NA | NA | NA | 0.00 |
Minority Interest | 0.00 | NA | NA | NA | 0.00 |
Investment Gains/Losses | 0.00 | NA | NA | NA | 0.00 |
Other Income/Charges | 0.00 | NA | NA | NA | 0.00 |
Income From Cont. Operations | -17.42 | NA | NA | NA | -12.17 |
Extras & Discontinued Operations | 0.00 | NA | NA | NA | 0.00 |
Net Income (GAAP) | -17.42 | NA | NA | NA | -12.17 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | 25.05 | NA | NA | NA | NA |
Diluted EPS Before Non-Recurring Items | -0.70 | NA | NA | NA | NA |
Diluted Net EPS (GAAP) | -0.70 | NA | NA | NA | NA |